3-aminoazetidine dihydrochloride | 102065-89-4

• 物质功能分类: 医药中间体
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环丁烷
• 英文名称: 3-aminoazetidine dihydrochloride
• 英文别名: azetidin-3-amine dihydrochloride；Azetidin-3-amine hydrochloride；azetidin-3-amine;hydrochloride
• CAS: 102065-89-4
• 化学式: C₃H₈N₂*2ClH
• 分子量: 145.032
• InChiKey: YQXHUNCYUWWGEV-UHFFFAOYSA-N

物化性质

• 熔点：
  162-163 ºC

计算性质

• 辛醇/水分配系数(LogP)：
  -0.66
• 重原子数：
  6
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  38
• 氢给体数：
  3
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335

制备方法与用途

概述

3-氨基氮杂环丁烷二盐酸盐可用作医药合成中间体。如吸入该物质，请将其移至空气新鲜处；若皮肤接触，应脱去污染衣物，并用肥皂水和清水彻底清洗皮肤，如有不适，请就医；若眼睛接触，需分开眼睑，使用流动清水或生理盐水冲洗，并立即就医；若误食，应立即漱口，禁止催吐，并尽快就医。

反应信息

• 作为反应物：
  描述：

  德拉沙星中间体4 、 3-aminoazetidine dihydrochloride 在 三乙胺 作用下， 以 乙腈 为溶剂， 反应 3.0h， 以27%的产率得到ethyl 1-(6-amino-3,5-difluoropyridin-2-yl)-7-(3-aminoazetidin-1-yl)-8-chloro-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate
  参考文献：
  名称：

  Novel C-7 carbon substituted fourth generation fluoroquinolones targeting N. Gonorrhoeae infections

  摘要：

  Delafloxacin, a fourth-generation anionic fluoroquinolone (FQ) was approved in 2019 for community acquired bacterial pneumonia (CARP). It has broad spectrum activity and an improved class-related toxicity profile. However, it has recently failed a Phase 3 clinical trial for treatment of N. gonorrhoeae infections due to the lack of sufficient efficacy at the dose administered.Inspired by the microbiological and safety profile of delafloxacin, we have developed and profiled the first reported delafloxacin carbon analogue whereby a Nitrogen-for-Carbon swap has been successfully carried out at the C7 position. Not only have we shown that compounds with this modification maintain activity against N. gonorrhoeae (plus other gram-positive and gram-negative bacteria) but they also demonstrate a differentiated physicochemical profile.A zwitterionic derivative of delafloxacin was also profiled and demonstrated a superior microbiological profile against gram-negative strains, whilst maintaining favorable selected ADMET properties.

  DOI：

  10.1016/j.bmcl.2020.127428
• 作为产物：
  描述：

  1-(diphenylmethyl)-3-azidoazetidine 在 palladium on activated charcoal 盐酸 、 氢气 作用下， 以 甲醇 为溶剂， 生成 3-aminoazetidine dihydrochloride
  参考文献：
  名称：

  抗菌剂，7-杂环胺取代的1-环丙基-6,8-二氟-4-氧喹啉-3-羧酸的定量构效关系。

  摘要：

  各种7-（3-取代的氮杂环丁烷-1-基）-1-环丙基-6,8-二氟-1,4-二氢4-氧代喹啉-3-羧酸的定量构效关系（QSAR），研究了14-25，以阐明3-取代的氮杂环丁烷增强抗菌活性的结构要求。在针对五个代表性革兰氏阴性细菌的相对平均抗菌活性指数GNM与这些分子的计算疏水参数CLOG P之间似乎存在良好的抛物线关系。最有效的导数的CLOG P值预计约为2.3。另一方面，相对于五个代表性的革兰氏阳性细菌，相对于平均抗菌活性指数GPM仍然很高，并且相当恒定，而与氮杂环丁烷部分的结构变化无关。为了证实这些发现，QSAR分析成功地扩展到了喹诺酮羧酸26-34，它带有各种取代的吡咯烷，哌嗪和哌啶衍生物，而不是氮杂环丁烷。结果表明，将任何酰胺取代基引入这些杂环胺部分将导致GNM显着降低，而在远离N-1位置的两个或三个碳原子处引入一些氨基取代基会大大增强GNM。由于氮杂环丁烷喹诺酮类药物在体内的抗菌

  DOI：

  10.1248/cpb.41.126

文献信息

• Synthesis and Antibacterial Activity of Novel 1.BETA.-Methyl Carbapenems with Cycloalkylamine Moiety at the C-2 Position.
  作者：ISAO KAWAMOTO、YASUO SHIMOJI、OSAMU KANNO、ROKURO ENDO、MASAO MIYAUCHI、KATSUHIKO KOJIMA、KATSUYA ISHIKAWA、MUNETSUGU MORIMOTO、SATOSHI OHYA

  DOI：10.7164/antibiotics.54.1080

  日期：——

  Novel 1β-methyl carbapenems with a cycloalkylamine moiety as a side chain were synthesized and their structure-activity relationships were studied. These carbapenems showed potent antibacterial activities against a wide range of Gram-positive and Gram-negative bacteria, and moderate urinary recovery when administered intraperitoneally in mice.

  具有环烷基胺侧链的新型1β-甲基碳青霉烯类化合物被合成，并研究了它们的构效关系。这些碳青霉烯类化合物对广泛的革兰氏阳性和革兰氏阴性细菌展现出强大的抗菌活性，并且在小鼠腹腔给药时具有中等程度的尿液回收率。
• [EN] NOVEL ULK1 INHIBITORS AND METHODS USING SAME<br/>[FR] NOUVEAUX INHIBITEURS D'ULK 1 ET LEURS MÉTHODES D'UTILISATION
  申请人：SALK INST FOR BIOLOGICAL STUDI

  公开号：WO2016033100A1

  公开（公告）日：2016-03-03

  In certain aspects, the invention provides a method for treating a disease or condition in a subject, the method comprising co-administering to a subject in need thereof a therapeutically effective amount of at least one ULK1-inhibiting pyrimidine, and a therapeutically effective amount of an mTOR inhibitor.

  在某些方面，该发明提供了一种治疗受试者疾病或病况的方法，该方法包括向需要的受试者联合给予至少一种ULK1抑制嘧啶的治疗有效量，以及mTOR抑制剂的治疗有效量。
• Pyridonecarboxylic acid derivatives or their salts and antibacterial
  申请人：Wakunaga Pharmaceuticals Co., Ltd.

  公开号：US05998436A1

  公开（公告）日：1999-12-07

  A pyridonecarboxylic acid derivative represented by the following general formula (1): ##STR1## [wherein R.sup.1 represents hydrogen atom or a carboxyl protective group; R.sup.2 represents hydroxyl group, a lower alkoxy group, or a substituted or unsubstituted amino group; R.sup.3 represents hydrogen atom or a halogen atom; R.sup.4 represents hydrogen atom or a halogen atom; R.sup.5 represents a halogen atom or an optionally substituted saturated cyclic amino group; R.sup.6 represents hydrogen atom, a halogen atom, nitro group, or an optionally protected amino group; X, Y and Z may be the same or different and respectively represent nitrogen atom, --CH.dbd. or --CR.sup.7 .dbd. (wherein R.sup.7 represents a lower alkyl group, a halogen atom, or cyano group) (with the proviso that at least one of X, Y and Z represent the nitrogen atom), and W represents nitrogen atom or --CR.sup.8 .dbd. (wherein R.sup.8 represents hydrogen atom, a halogen atom, or a lower alkyl group)] or its salt, as well as an antibacterial agent containing such compound are provided.

  一种吡啶酮羧酸衍生物，由以下通式（1）表示： ##STR1## [其中R1表示氢原子或羧基保护基团；R2表示羟基、低级烷氧基或取代或未取代的氨基；R3表示氢原子或卤素原子；R4表示氢原子或卤素原子；R5表示卤素原子或可选择性取代的饱和环状氨基；R6表示氢原子、卤素原子、硝基或可选择性保护的氨基；X、Y和Z可以相同或不同，分别表示氮原子、--CH＝或--CR7＝（其中R7表示低级烷基、卤素原子或氰基）（条件是X、Y和Z中至少有一个表示氮原子），W表示氮原子或--CR8＝（其中R8表示氢原子、卤素原子或低级烷基）]或其盐，以及含有此类化合物的抗菌剂。
• NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVE OR SALT THEREOF
  申请人：WAKUNAGA PHARMACEUTICAL CO., LTD.

  公开号：US20190276407A1

  公开（公告）日：2019-09-12

  A pyridonecarboxylic acid derivative or a salt thereof is represented by Formula (1), where R 1 is hydrogen, a halogen atom, a lower alkyl group, or an amino group; R 2 is —NH—R 6 , where R 6 is hydrogen, a lower alkyl group, an amino lower alkyl group, or the like; —O—R 7 , where R 7 is hydrogen, a lower alkyl group, or the like; —(CH 2 ) m —R 8 , where R 8 is an amino group or the like, m is 1, 2, 3 or 4; or a cyclic amino group of Formula (2), where Y represents NH or C—R 9a R 9b , where R 9a and R 9b are each independently hydrogen, a lower alkyl group, an amino group, a lower alkyl amino group, or the like; n and p are 1 or 2; R 3 is hydrogen, a halogen atom, a lower alkyl group, or the like; R 4 is hydrogen or a carboxyl group-protecting group; and R 5 is hydrogen or a hydroxyl group-protecting group.

  化合物或其盐可由以下式（1）表示，其中R1是氢、卤素原子、低烷基或氨基；R2是—NH—R6，其中R6是氢、低烷基、氨基低烷基或类似物；—O—R7，其中R7是氢、低烷基或类似物；—(CH2)m—R8，其中R8是氨基或类似物，m为1、2、3或4；或由以下式（2）的环状氨基团表示，其中Y代表NH或C—R9aR9b，其中R9a和R9b各自独立地是氢、低烷基、氨基、低烷基氨基或类似物；n和p为1或2；R3是氢、卤素原子、低烷基或类似物；R4是氢或羧基保护基团；R5是氢或羟基保护基团。
• Pyridonecarboxylic acid derivatives or salts thereof and antibacterial
  申请人：Wakunaga Seiyaku Kabushiki Kaisha

  公开号：US05910498A1

  公开（公告）日：1999-06-08

  The invention provides a pyridonecarboxylic acid derivative of the following general formula (1): ##STR1## wherein R.sup.1 is a hydrogen atom or carboxy protecting group, R.sup.2 is a nitro or substituted or unsubstituted amino group, R.sup.3 is a halogen atom, each of R.sup.4 and R.sup.5, which may be the same or different, is a hydrogen atom, halogen atom, lower alkyl group or lower alkoxy group, A is a nitrogen atom or --CX.dbd. wherein X is a hydrogen atom, halogen atom, lower alkyl group or lower alkoxy group, and Z is a halogen atom or a saturated cyclic amino group which may have a substituent, or a salt thereof and an antibacterial agent comprising the same.

  该发明提供了以下一般式（1）的吡啶酮羧酸衍生物： 其中R.sup.1是氢原子或羧基保护基，R.sup.2是硝基或取代或未取代的氨基，R.sup.3是卤素原子，R.sup.4和R.sup.5中的每一个，可以相同也可以不同，是氢原子、卤素原子、低烷基基团或低烷氧基团，A是氮原子或--CX.dbd.，其中X是氢原子、卤素原子、低烷基基团或低烷氧基团，Z是卤素原子或饱和环状氨基团，可能带有取代基，或其盐以及包含其的抗菌剂。